PORTLAND, ME – Consigli Construction Co., Inc. announced that it broke ground on the new facility for ImmuCell Corporation (ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries. Located in Portland, the new pharmaceutical facility will produce Nisin, the active ingredient in Mast Out®.
“Through its construction and when it is complete, this facility will ultimately result in many local jobs,” commented Dave Thomas, Project Executive for Consigli Construction. “We are excited to be a part of something that will have a lasting impact on our community and will continue to contribute to the regional economy in such a significant manner for years to come.”
“Initiating the site construction phase of this extensive project is a key milestone resulting from over 15 years of investment in product development and production scale-up for this novel mastitis treatment for dairy cows,” commented Elizabeth L. Williams, VP of Manufacturing Operations for ImmuCell.
Stantec Consulting Services Inc. is providing design and engineering services. Consigli Construction is serving as construction manager on this project.
The two-story facility, which is being built nearby to the ImmuCell’s headquarters and USDA production facility, will provide more than 16,800 square feet of fermentation, processing, laboratory and warehouse space on a footprint of 12,625 square feet for the production of the active ingredient in Mast Out®. The estimated budget for this project is approximately $20 million.
Plans call for construction to be complete by the third quarter of 2017 and for equipment installation to be complete by the first quarter of 2018.